Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages 435-440

  Liu, Yu ^a   Yang, Jie ^a   Xu, Qiang ^a   Xu, Bin ^a   Gao, Lei ^a   Zhang, Yuxiao ^a   Zhang, Yan ^a   Wang, Hongjuan ^a   Lu, Caiyi ^a   Zhao, Yusheng ^a   Yin, Tong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CYP2C9; CYP4F2; low intensity anticoagulation; pharmacogenetics; VKORC1; Warfarin

Indexed keywords

GENOMIC DNA; WARFARIN;

ACCURACY; ADULT; ANTICOAGULANT THERAPY; ARTICLE; ASIAN; CAUCASIAN; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DRUG DOSE REGIMEN; DRUG MEGADOSE; ETHNIC DIFFERENCE; FEMALE; GENE; GENE FREQUENCY; GENETIC ALGORITHM; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ALGORITHMS; CHINA; DECISION SUPPORT SYSTEMS, CLINICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHARMACOGENETICS; PREVALENCE; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 84865263867     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.003     Document Type: Article

References (40)

1. S.C. Cannegieter, F.R. Rosendaal, A.R. Wintzen, F.J. van der Meer, J.P. Vandenbroucke, and E. Briet Optimal oral anticoagulant therapy in patients with mechanical heart valves N Engl J Med 333 1995 11 17
2. S.D. Fihn, M. McDonell, D. Martin, J. Henikoff, D. Vermes, and D. Kent Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 1993 511 520
3. D. Voora, H.L. McLeod, C. Eby, and B.F. Gage The pharmacogenetics of coumarin therapy Pharmacogenomics 6 2005 503 513
4. T. Yin, and T. Miyata Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives Thromb Res 120 2007 1 10
5. S.A. Lubitz, S.A. Scott, E.B. Rothlauf, A. Agarwal, I. Peter, and D. Doheny Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population J Thromb Haemost 8 2010 1018 1026
6. A.H. Wu, P. Wang, A. Smith, C. Haller, K. Drake, and M. Linder Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations Pharmacogenomics 9 2008 169 178
7. H. Sagreiya, C. Berube, A. Wen, R. Ramakrishnan, A. Mir, and A. Hamilton Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9 Pharmacogenet Genomics 20 2010 407 413
8. P. Lenzini, M. Wadelius, S. Kimmel, J.L. Anderson, A.L. Jorgensen, and M. Pirmohamed Integration of genetic, clinical, and INR data to refine warfarin dosing Clin Pharmacol Ther 87 2010 572 578
9. J. Shin, and D. Cao Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort Pharmacogenomics 12 2010 125 134
10. N. Roper, B. Storer, R. Bona, and M. Fang Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing J Mol Diagn 12 2010 283 291
11. L. Dong, Y.K. Shi, Z.P. Tian, J.Y. Ma, X. Wang, and J. Yi Low intensity anticoagulation therapy after mechanical heart valve replacement Zhonghua Wai Ke Za Zhi 41 2003 250 252
12. J.H. You, F.W. Chan, R.S. Wong, and G. Cheng Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 59 2005 582 587
13. X. Sun, S. Hu, G. Qi, and Y. Zhou Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves Chin Med J (Engl) 116 2003 1175 1178
14. M. Yasaka, K. Minematsu, and T. Yamaguchi Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation Intern Med 40 2001 1183 1188
15. P.M. Ridker, S.Z. Goldhaber, E. Danielson, Y. Rosenberg, C.S. Eby, and S.R. Deitcher Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism N Engl J Med 348 2003 1425 1434
16. S.Z. Goldhaber Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy J Thromb Thrombolysis 21 2006 51 52
17. P.B. Shaw, J.L. Donovan, M.T. Tran, S.C. Lemon, P. Burgwinkle, and J. Gore Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic J Thromb Thrombolysis 30 2010 220 225
18. T. Yin, K. Maekawa, K. Kamide, Y. Saito, H. Hanada, and K. Miyashita Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan Hypertens Res 31 2008 1549 1557
19. T.E. Klein, R.B. Altman, N. Eriksson, B.F. Gage, S.E. Kimmel, and M.T. Lee Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
20. B.F. Gage, C. Eby, J.A. Johnson, E. Deych, M.J. Rieder, and P.M. Ridker Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 2008 326 331
21. J.A. Johnson, L. Gong, M. Whirl-Carrillo, B.F. Gage, S.A. Scott, and C.M. Stein Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing Clin Pharmacol Ther 90 2010 625 629
22. B.S. Finkelman, B.F. Gage, J.A. Johnson, C.M. Brensinger, and S.E. Kimmel Genetic warfarin dosing: tables versus algorithms J Am Coll Cardiol 57 2011 612 618
23. S.W. Huang, H.S. Chen, X.Q. Wang, L. Huang, D.L. Xu, and X.J. Hu Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients Pharmacogenet Genomics 19 2009 226 234
24. M. Ohno, A. Yamamoto, A. Ono, G. Miura, M. Funamoto, and Y. Takemoto Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients Eur J Clin Pharmacol 65 2009 1097 1103
25. E.A. Sconce, T.I. Khan, H.A. Wynne, P. Avery, L. Monkhouse, and B.P. King The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2005 2329 2333
26. H. Takahashi, G.R. Wilkinson, E.A. Nutescu, T. Morita, M.D. Ritchie, and M.G. Scordo Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet Genomics 16 2006 101 110
27. C.F. Zambon, V. Pengo, R. Padrini, D. Basso, S. Schiavon, and P. Fogar VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study Pharmacogenomics 12 2011 15 25
28. L. Miao, J. Yang, C. Huang, and Z. Shen Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients Eur J Clin Pharmacol 63 2007 1135 1141
29. M.D. Caldwell, T. Awad, J.A. Johnson, B.F. Gage, M. Falkowski, and P. Gardina CYP4F2 genetic variant alters required warfarin dose Blood 111 2008 4106 4112
30. P. Borgiani, C. Ciccacci, V. Forte, E. Sirianni, L. Novelli, and P. Bramanti CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population Pharmacogenomics 10 2009 261 266
31. F. Takeuchi, R. McGinnis, S. Bourgeois, C. Barnes, N. Eriksson, and N. Soranzo A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genet 5 2009 e1000433
32. H.J. Cen, W.T. Zeng, X.Y. Leng, M. Huang, X. Chen, and J.L. Li CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement Br J Clin Pharmacol 70 2010 234 240
33. N.A. Limdi, M. Wadelius, L. Cavallari, N. Eriksson, D.C. Crawford, and M.T. Lee Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups Blood 115 2010 3827 3834
34. L.H. Cavallari, and N.A. Limdi Warfarin pharmacogenomics Curr Opin Mol Ther 11 2009 243 251
35. Q. Gu, Y. Kong, J. Schneede, Y.B. Xiao, L. Chen, and Q.J. Zhong VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China Eur J Clin Pharmacol 66 2010 1217 1227
36. M.T. Lee, C.H. Chen, C.H. Chou, L.S. Lu, H.P. Chuang, and Y.T. Chen Genetic determinants of warfarin dosing in the Han-Chinese population Pharmacogenomics 10 2009 1905 1913
37. T. Harada, N. Ariyoshi, H. Shimura, Y. Sato, I. Yokoyama, and K. Takahashi Application of Akaike information criterion to evaluate warfarin dosing algorithm Thromb Res 126 2010 183 190
38. J.H. You, R.S. Wong, M.M. Waye, Y. Mu, C.K. Lim, and K.C. Choi Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients J Thromb Thrombolysis 31 2011 113 118
39. M. Wadelius, L.Y. Chen, K. Downes, J. Ghori, S. Hunt, and N. Eriksson Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 2005 262 270
40. D. Herman, P. Peternel, M. Stegnar, K. Breskvar, and V. Dolzan The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Thromb Haemost 95 2006 782 787